Skip to content

Efficacy of Lohasava and Amalaki Churna in the management of Anemia (Pandu)

Clinical Evaluation of Lohasava and Amalaki Churna in the management of Iron Deficiency Anemia (Pandu)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/10/021592
Enrollment
120
Registered
2019-10-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Lohasava : Dose-20 ml mixed with equal amount of water Frequency-twice daily Route of Administration-Oral Time of Administration-twice daily after food Anupana-water Duration Therapy-1

Sponsors

Central Council For Research In Ayurvedic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. (i) Hb 8gm-10gm.% (ii) S.Ferritin (iii) TIBC level >450mcg/dL (iv) S.Iron (v) MCV level (vi) RDW >46fL (vii) Reticulocyte count (Among these the first 3 are the essential criteria for inclusion) 2. Willing and able to participate for 112 days.

Exclusion criteria

Exclusion criteria: 1. Iron deficiency likely or definitely due to blood loss from the intestine or other sites. 2. History or evidence of intestinal malabsorption 3. Major co-morbidity such as a serious chronic medical condition unrelated to iron deficiency apparent on history, physical examination or laboratory tests 4. Other causes of anemia (sickle cell disease, thalassemia,other hemolytic anemia, bone marrow failure, etc.) apparent by history, physical examination, and/or laboratory tests 5. Liver enzymes, AST/ALT > 2 x the upper limit;serum creatinine more than the upper limit. 6. Patients on prolonged ( > 6 weeks) medication that may have an influence on the outcome of the study 7. Other medical or social factors at discretion of treating physician

Design outcomes

Primary

MeasureTime frame
Change in Hemoglobin percentageTimepoint: Baseline, and 84th day

Secondary

MeasureTime frame
Change in Serum ferritin level Change in Serum iron level Change in Ayurvedic Parameters of Pandu roga Change in Peripheral Blood Smear PictureTimepoint: Lab investigations on Baseline, and 84th day Clinical assesment on Baseline, 14th, 28th, 42nd, 56th, 70th, 84th and 112nd day

Countries

India

Contacts

Public ContactDr Om Prakash

Regional Ayurveda Research Institute for Drug Development. Aamkho, Gwalior

oprakash749@gmail.com09406581637

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026